BLOG

GigaGen Publishes Data on New Recombinant Hyperimmune Drug Class as COVID-19 Therapy

Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}